Full history for every metric is available with a Kvantra account
Neovasc Inc. (NVCN.TO)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 5 | 2 | 2 | 2 | 3 | 4 | 4 |
| Operating profit | $m | -34 | -34 | |||||
| Net profit | $m | -23 | -108 | -35 | -29 | -25 | -41 | -47 |
| EPS reported | $ | 0.00 | -12.29 | |||||
| Operating cashflow per share | $ | 0.00 | 0.00 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | 0.00 | 0.00 | |||||
| Free cash flow | $m | -25 | -25 | |||||
| Net debt | $m | -13 | -13 | |||||
| Book value equity | $m | 16 | 16 | |||||
| Book value per share | $ | 0.00 | 0.00 | |||||
| Number of shares | m | - | - | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.73 | 4.91 | |||||
| P/S LTM | x | 11.38 | 20.43 | |||||
| P/FCF LTM | x | -1.73 | -3.11 | |||||
| EV/EBITDA LTM | x | -0.78 | -1.64 | |||||
| EV/Sales LTM | x | -3.36 | 16.98 | |||||
| Earnings Yield LTM | % | 0.00% | 0.00% | |||||
| FCF Yield | % | -57.68% | -32.13% | |||||
| Quality | ||||||||
| ROE | % | -260.14% | -121.07% | |||||
| ROIC | % | -116.83% | -116.83% | |||||
| Operating margin | % | -886.75% | -886.75% | |||||
| Gross margin | % | 79.66% | 79.66% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +49.37% | +49.37% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.92 | -1.92 | |||||
| Net Debt/EBITDA | x | 0.33 | 0.33 | |||||
| EBIT/Net interest | x | -22.23 | -22.23 | |||||
| Net debt/market cap | % | -29.54% | -16.92% | |||||
| Net debt/Equity | x | -0.81 | -0.83 | |||||
| Gross debt/equity | x | 0.82 | 0.82 | |||||
Company overview
Neovasc Inc. is a medical technology firm specializing in the design, production, and global distribution of cardiovascular devices, particularly across European markets and beyond. Its primary offerings include the Tiara system, developed for the transcatheter treatment of mitral valve disease, and the Neovasc Reducer, used to address chronic, debilitating chest pain known as refractory angina. Established in 2000, the company, which maintains its headquarters in Richmond, Canada, was formerly named Medical Ventures Corp. before adopting its current identity, Neovasc Inc., in July 2008.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Neovasc Inc. (NVCN.TO)
Neovasc Inc. is a medical technology firm specializing in the design, production, and global distribution of cardiovascular devices, particularly across European markets and beyond. Its primary offerings include the Tiara system, developed for the transcatheter treatment of mitral valve disease, and the Neovasc Reducer, used to address chronic, debilitating chest pain known as refractory angina. Established in 2000, the company, which maintains its headquarters in Richmond, Canada, was formerly named Medical Ventures Corp. before adopting its current identity, Neovasc Inc., in July 2008.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free